Trovagene, Inc. Announces Pricing of Public Offering of 1, 150, 000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split

SAN DIEGO, May 29, 2012 /PRNewswire/ --  Trovagene, Inc. (Nasdaq: TROVD), a developer of trans-renal molecular diagnostics, announced the pricing of an underwritten public offering of 1,150,000 units at an offering price of $8.00 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will begin trading on The NASDAQ Capital Market on May 30, 2012 under the symbol "TROVU". The common stock and warrants will not be separ...continued TROV

URL: http://www.investorpoint.com/news/INTHPINK/51641731/